Pascal Touchon, Atara CEO

Fu­ji­film com­pletes ac­qui­si­tion of Atara's cell ther­a­py man­u­fac­tur­ing site near Los An­ge­les

In Jan­u­ary, Atara Bio­ther­a­peu­tics inked a deal with Fu­ji­film Diosynth to ex­change its Cal­i­for­nia man­u­fac­tur­ing site for $100 mil­lion up­front, and a long-term li­cens­ing deal for its al­lo­gene­ic T-cell ther­a­py plat­form for pa­tients with can­cer and au­toim­mune dis­ease. Mon­day, the biotech an­nounced that the deal has now been com­plet­ed, and the part­ner­ship has be­gun.

Fu­ji­film Diosynth will now give Atara ac­cess to the flex ca­pac­i­ty to man­u­fac­ture both clin­i­cal and com­mer­cial stage ther­a­pies for tab-cel, its off-the-shelf, al­lo­gene­ic T-cell im­munother­a­py in de­vel­op­ment for the treat­ment of Ep­stein-Barr virus pos­i­tive post-trans­plant lym­pho­pro­lif­er­a­tive dis­ease, its can­di­date ATA188 for mul­ti­ple scle­ro­sis, and al­lo­gene­ic CAR-T ther­a­pies ATA3271 and ATA3219.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.